Page last updated: 2024-09-03

omega-n-methylarginine and Triple Negative Breast Neoplasms

omega-n-methylarginine has been researched along with Triple Negative Breast Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Anand, K; Anselme, AC; Belcheva, A; Bernicker, E; Chan, AA; Chang, JC; Chen, SH; Chung, AW; Darcourt, J; Ensor, J; Gupta, N; Kuhn, J; Lee, DJ; Niravath, PA; Pan, PY; Patel, T; Qian, W; Rodriguez, AA; Schwartz, MR; Venta, LA; Xu, Y; Zhang, L	1
Firger, J	1
Chang, JC; Dave, B; Elemento, O; Ensor, JE; Ezzedine, NE; Gilcrease, MZ; Gonzalez, DD; Granados, S; Gross, SS; KarinaEtrovic, A; Li, X; Liu, ZB; Miller, KD; Mills, GB; Radovich, M; Sieglaff, DH; Wong, H	1

Trials

1 trial(s) available for omega-n-methylarginine and Triple Negative Breast Neoplasms

Article	Year
A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Science translational medicine, 2021, 12-15, Volume: 13, Issue:624 Topics: Enzyme Inhibitors; Humans; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Taxoids; Triple Negative Breast Neoplasms	2021

Other Studies

2 other study(ies) available for omega-n-methylarginine and Triple Negative Breast Neoplasms

Article	Year
Nitric Oxide Inhibitors Hit Target for Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2015, Volume: 107, Issue:8 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Enzyme Inhibitors; Female; Humans; Methotrexate; Nitric Oxide; Nitric Oxide Synthase Type II; omega-N-Methylarginine; Triple Negative Breast Neoplasms	2015
Role of RPL39 in Metaplastic Breast Cancer. Journal of the National Cancer Institute, 2017, Volume: 109, Issue:6 Topics: Adenosine Deaminase; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Enzyme Inhibitors; Female; Humans; Kaplan-Meier Estimate; Metaplasia; Mice; Mutation Rate; Neoplasm Transplantation; Nitrates; Nitric Oxide Synthase Type II; Nitrites; omega-N-Methylarginine; Ribosomal Proteins; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Survival Rate; Triple Negative Breast Neoplasms; Ubiquitin C	2017

Article

Year

Nitric Oxide Inhibitors Hit Target for Triple-Negative Breast Cancer.

Journal of the National Cancer Institute, 2015, Volume: 107, Issue:8

Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Enzyme Inhibitors; Female; Humans; Methotrexate; Nitric Oxide; Nitric Oxide Synthase Type II; omega-N-Methylarginine; Triple Negative Breast Neoplasms

2015

Role of RPL39 in Metaplastic Breast Cancer.

Journal of the National Cancer Institute, 2017, Volume: 109, Issue:6

Topics: Adenosine Deaminase; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Enzyme Inhibitors; Female; Humans; Kaplan-Meier Estimate; Metaplasia; Mice; Mutation Rate; Neoplasm Transplantation; Nitrates; Nitric Oxide Synthase Type II; Nitrites; omega-N-Methylarginine; Ribosomal Proteins; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Survival Rate; Triple Negative Breast Neoplasms; Ubiquitin C

2017